Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands
This article was originally published in The Rose Sheet
Executive SummaryLatisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.
You may also be interested in...
Two cosmetics companies have settled charges filed by Tennessee’s Office of the Attorney General concerning eyelash-enhancement products that require FDA approval, according to the AG’s release. Tennesseans will no longer have access to Nutra Luxe’s Beautylash products or Peter Thomas Roth’s Lashes to Die For as a result of the agreement.
Latisse maker Allergan prevails in California district court over cosmetic eyelash-enhancement marketer Athena Cosmetics, which has been enjoined from selling RevitaLash in the U.S. More news in brief.
Lawsuit seeking class-action status against Coty alleges that lengthening and multiplying claims for the firm’s Rimmel London Lash Accelerator are “false, misleading and are reasonably likely to deceive the public.”